Document Detail


Reduction of hyperinflation by pharmacologic and other interventions.
MedLine Citation:
PMID:  16565430     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hyperinflation of the lungs is associated with activity limitation and reduced quality of life of patients with chronic obstructive pulmonary disease (COPD). Cardiopulmonary exercise testing has proven useful, not only in establishing this link, but also in determining which interventions modify exercise endurance and the mechanisms by which this is achieved. In COPD, dynamic hyperinflation is reduced during exercise by interventions that either increase the potential for expiratory flow or increase the time available for expiration. Two classes of intervention improve exercise tolerance by increasing expiratory flow. Bronchodilators reduce expiratory airflow resistance by increasing the diameter of the airways. An alternative intervention, though less practical, is to reduce the density of the gas exhaled through obstructed airways, such as occurs when breathing a mixture of helium and oxygen (heliox). In contrast, supplemental oxygen and exercise rehabilitation programs improve endurance by reducing respiratory ventilatory drive and, therefore, respiratory rate. The different mechanisms exploited by these interventions to reduce dynamic hyperinflation suggest that combination treatments should yield additive benefits. This has been proven in the case of combinations of rehabilitative exercise training with supplemental oxygen, or with the bronchodilator tiotropium, both of which have been found to yield additive effects. With such interventions, we already have options for improving the mobility of patients with COPD. With a firm understanding of the physiologic basis of exercise limitation, we can focus on defining new and better strategies to improve exercise tolerance.
Authors:
Richard Casaburi; Janos Porszasz
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Proceedings of the American Thoracic Society     Volume:  3     ISSN:  1546-3222     ISO Abbreviation:  Proc Am Thorac Soc     Publication Date:  2006 Apr 
Date Detail:
Created Date:  2006-03-27     Completed Date:  2006-08-31     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  101203596     Medline TA:  Proc Am Thorac Soc     Country:  United States    
Other Details:
Languages:  eng     Pagination:  185-9     Citation Subset:  IM    
Affiliation:
Rehabilitation Clinical Trials Center, Los Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles Medical Center, Torrance, California 90502, USA. casaburi@ucla.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Bronchodilator Agents / therapeutic use
Exercise Therapy
Exercise Tolerance / physiology
Helium / therapeutic use
Humans
Lung Volume Measurements*
Oxygen / therapeutic use
Oxygen Inhalation Therapy
Pulmonary Disease, Chronic Obstructive / physiopathology,  therapy*
Chemical
Reg. No./Substance:
0/Bronchodilator Agents; 58933-55-4/heliox; 7440-59-7/Helium; 7782-44-7/Oxygen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease.
Next Document:  Role of nitric oxide in cardiovascular adaptation to intermittent hypoxia.